必可酮吸入剂与甲泼尼龙在AECOPD治疗中的疗效观察

目的观察评价必可酮（丙酸倍氯米松）吸入治疗慢性阻塞性肺疾病急性加重期的临床疗效.方法 将56例选入病例随机分为治疗A组和对照B组,其中A组27例,B组29例.两组均给予控制感染支气管扩张剂,保持气道通畅,持续低流量吸氧、止咳、化痰,维持水、电解质、酸碱平衡,营养支持等综合疗法.A组在此基础上加用必可酮（丙酸倍氯米松）,3～4喷/d（0.05～0.1 mg）吸入;B组给予甲泼尼龙40 mg/次静点,2次/d,连用7 d后给予评分.结果 治疗后两组在咳嗽、咳痰、喘息及肺部哮鸣音等方面均有明显改善（P〈0.01）,并且两组治疗上述情况改善无明显统计学意义（P〉0.05）,A组治疗过程中无不良反应发生.结论 必可酮气雾剂吸入治疗慢性阻塞性肺疾病急性加重期临床疗效确切、安全.

Effect Observation of Beclomethasone Dipropionate Combined with Methylprednisolone on Chronic Obstructive Pulmonary Disease

Objective To observe and evaluate the clinical effect of Beclomethasone dipropionate on chronic obstructive pulmonary disease at acute exacerbation stage.Method 56 cases with chronic obstructive pulmonary disease are divided into group A（27 cases） and B（29 cases） randomly.Two groups are used bronchodilator agents to keep airway unobstructed and received basic therapy including anti-infection,relieving airway spasm and asthma,and maintenance of electrolyte and acid base balances,etc.Group A is added Beclomethasone dipropionate based on above it,3~4 times/d（inhaling 0.05~0.1 mg）.Group B is injected with Methylprednisolone 40mg,2 times/d,successive application for 7 days.Results Two groups have significant improvement in cough,sputum,gasp and lung wheezing after treatment（P0.01）,both of them have no obvious difference（P0.05）.Conclusion The clinical effect of beclomethasone dipropionate on chronic obstructive pulmonary disease at acute exacerbation stage is safe and obviously curative.